AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02584439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ivabradine
Description: It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
Study NCT02584439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lactose capsule (placebo)
Description: It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
Study NCT02959580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Butyrate
Description: topical use
Study NCT02959580 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extended excision
Description: Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
Study NCT00723710 — intervention group
Intervention type: BIOLOGICAL
Intervention: Intron A (interferon alfa-2b; SCH 30500)
Description: The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m\^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m\^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
Study NCT00509561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00509561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT01805765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qing'E pills
Description: composed of eucommia, psoralen, walnuts and garlic
Study NCT01805765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Containing 2% of Qing'E pills
Study NCT04376411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow-cytometric assay
Description: 100 µl of blood sample was incubated for 20 minutes at 4 C in the dark. Following incubation, red blood cells lysis, washing and analysis a specific software.Forward and side scatter histogram was used to define the lymphocytes population.
Study NCT04555148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02763969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986202
Study NCT00509561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00509561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study NCT00509561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT04187521 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meal A
Description: A breakfast meal with a specific macronutrient proportions.
Study NCT00896961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study NCT00896961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT01891643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02763969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02763969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a recombinant
Study NCT02763969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Study NCT02763969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Study NCT01466543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zydena (Udenafil)
Description: Zydena (Udenafil) 100 mg, one time
Study NCT01466543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01599143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Mindfulness-based Stress Reduction strategies
Description: Daily meditation, Hatha yoga,and cognitive restructuring
Study NCT00480948 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula feeding (InFat™)
Description: Infant formula with InFat™ oil (containing \~49% of C16:0 at sn-2 position), 24 wk
Study NCT00480948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard vegetable oil based infant formula
Study NCT02643069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Geriatric Program
Description: The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
Study NCT02150408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-CT
Study NCT01173887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VCAP/AMP/VECP(mLSG15)
Description: VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
Study NCT01891643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01173887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: VCAP/AMP/VECP(mLSG15) + KW-0761
Study NCT04187521 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meal B
Description: A breakfast meal with a specific macronutrient proportions.
Study NCT05958693 — intervention group
Intervention type: DRUG
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for >35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (>13 years old)
Study NCT01891643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Study NCT01725139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2126458
Description: GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
Study NCT01725139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available
Study NCT03900780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PGT-A
Description: ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
Study NCT03900780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
Study NCT00565630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigamox delivered via the device in spray form
Description: Vigamox delivered 4 times, 1 hour prior to cataract surgery
Study NCT00565630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox delivered via the device in spray form
Description: Vigamox delivered 4 times, 1 hour prior to cataract surgery
Study NCT00023322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alpha-2a
Description: Treatment
Study NCT02490852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational infant formula
Description: fed ad libitum
Study NCT02490852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Commercially available Infant formula
Description: fed ad libitum
Study NCT02490852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Human milk
Description: fed ad libitum
Study NCT00110305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 25 mg
Description: TMC278 25 mg tablet will be administered once daily.
Study NCT00110305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 75 mg
Description: TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
Study NCT00110305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 150 mg
Description: TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
Study NCT00110305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
Study NCT00110305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Description: Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Study NCT00509561 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT00509561 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01825447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
Study NCT01825447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone + Naltrexone
Description: Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
Study NCT01825447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
Study NCT01215981 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
Study NCT01215981 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
Study NCT03067753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialoganglioside Ganglioside
Description: Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
Study NCT03067753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone (Steroid Hormone)
Description: Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
Study NCT03067753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study NCT02486445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)
Study NCT03325426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Daily use of physical activity tracker coupled with biweekly provider telemonitoring and feedback for 6 months and then additionally without feedback for an additional 6 months
Study NCT01633645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Velcade
Study NCT01633645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-days treatment cycle for a maximum of 8 cycles
Study NCT00110305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Description: Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Study NCT00961532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP injection (desmopressin acetate)
Description: 0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
Study NCT00337389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5- Fluorouracil (5-FU)
Study NCT00337389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5- Fluorouracil (5-FU)
Study NCT04376411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Echocardiographic analysis
Description: Trans thoracic echocardiographic examination was performed through (PHILIPS -33) echocardiography device with broadband S5-1 transducer
Study NCT04376411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Two-Dimensional speckle tracking echocardiography
Description: Two-Dimensional speckle tracking echocardiography was performed on grey scale images of the left ventricle. For offline analysis digital storage software (Qlab 10.4) was used. The frame rate was adjusted to be 60-90 frame/second.
Study NCT00337389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Study NCT00337389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab (Avastin)
Study NCT00337389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study NCT00337389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoFactor (ANX-510)
Study NCT05087888 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05087888 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo functional MRI
Study NCT05087888 — intervention group
Intervention type: PROCEDURE
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo multiparametric MRI
Study NCT05087888 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT00296335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin, doxifluridine and cisplatin
Description: Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
Study NCT00296335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin and doxifluridine
Description: Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
Study NCT01537588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autograft STG harvest from ACL-deficient leg
Description: Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction
Study NCT01537588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autograft harvest contralateral to ACL-deficient leg
Description: Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
Study NCT03934801 — intervention group
Intervention type: OTHER
Intervention: Brainstorming 1
Description: Expert recommendation statements will be collected for peer evaluation.
Study NCT03934801 — intervention group
Intervention type: OTHER
Intervention: Ranking Round 1
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
Study NCT03934801 — intervention group
Intervention type: OTHER
Intervention: Ranking Round 2
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
Study NCT03934801 — intervention group
Intervention type: OTHER
Intervention: Ranking Round 3
Description: Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
Study NCT04568200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg i.v. day 1-22-43-64
Study NCT04568200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT04568200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy
Study NCT04568200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy
Study NCT04568200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy
Study NCT04568200 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 23 x 1.8 Gy
Description: Radiotherapy 23 x 1.8 Gy
Study NCT04568200 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy 23 x 1.8 Gy
Description: Radiotherapy 23 x 1.8 Gy
Study NCT04951960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Higher PEEP setting
Description: PEEP levels are determined according to the higher PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
Study NCT04951960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lower PEEP setting
Description: PEEP levels are determined according to the lower PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
Study NCT04796467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-617
Description: Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
Study NCT04796467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-P16-093
Description: Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P16-093. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
Study NCT05322785 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breath collection
Description: Exhaled breath will be passively collected from subjects during quiet oral breathing through a simple mouthpiece or mask
Study NCT05958693 — intervention group
Intervention type: DRUG
Intervention: Primaquine
Description: For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
Study NCT01603524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OMSC Group
Description: The OMSC Group will receive a multi-component intervention which includes:~1. Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~2. Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~3. Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~4. Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program.
Study NCT01603524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OMSC + Performance Feedback Group
Description: The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
Study NCT01603524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OMSC + Performance Feedback Group
Description: The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
Study NCT03737071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet
Description: Ketogenic dietary intervention
Study NCT03737071 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simple Calorie Restriction Diet
Description: Simple calorie restriction dietary intervention